NADINA was a phase III, randomised trial of neoadjuvant nivolumab–ipilimumab (two cycles) versus adjuvant nivolumab in 423 patients with biopsy-proven, resectable stage III melanoma involving LNs ± a maximum of three ITMs.36 In the neoadjuvant group, only patients who had a pPR or pNR received subsequent adjuvant treatment with either dabrafenib–trametinib (for BRAF-mutated melanoma) or nivolumab. Here, BRAF is linked to melanoma.